Tumor Imaging: From Screening to Response Assessment

Online Course Package with Book

This course delivers the latest imaging information concerning lung, colorectal, and breast cancer. Participants will gain the interpretive, technical, and systems knowledge radiologists need to provide quality screening, while learning strategies to address overall care disparities. Providing a truly comprehensive review of oncologic imaging, additional discussions will address diagnostic workflows, enterprise solutions, new horizons in PET/MRI, and the role of AI. Response assessment criteria, including RECIST 1.1, iRECIST, and Lugano, as well as business models for establishing a response assessment lab will also be discussed.

ARRS Member price: $745
ARRS In-Training Member price: $375
Nonmember price: $995

Order Now

Or consider the stand-alone book.

View the Sample Recording

Earn credit at your own pace through June 20, 2025 and continue to access your videos until June 19, 2032. See below for detailed information and learning outcomes.

This course package offers 27 CME following completion of an online test.

Video content for this Online Course will be available to view until June 19, 2032, which is ten years following the issuance date of this course. ARRS reserves the right to remove video content before the end of the ten year period. Video content that contradicts current science or misleads the viewer based on changes to accepted clinical practice may be removed on a case-by-case basis.

Learning Outcomes and Modules  

After completing this course, the learner should be able to:

  • Describe techniques for optimal performance and interpretation of lung cancer screening examinations
  • Discuss optimal technique for performance and interpretation of CT colonography examinations for colorectal cancer screening
  • Describe the latest developments in breast cancer screening, including abbreviated MRI protocols and contrast-enhanced mammography
  • Explain various response assessment criteria for solid organ tumors, including RECIST 1.1, iRECIST, and Lugano
  • Discuss disparities in cancer screening and strategies to address disparities

Module 1Lung Cancer Screening, Missed Cases and Staging

  • Introduction to Lung Cancer Screening: Advancing Equity in Your Practice—Efren J. Flores, MD
  • Approach to Management of Difficult Nodules on Lung Cancer Screening CT—Suzanne C. Byrne, MD
  • Thoracic Malignancy Undercalls and Overcalls: A Practical Approach to Improve Accuracy—Lucy Modahl, MD, PhD
  • Imaging in Lung Cancer Staging and Modern Lung Cancer Treatment—Dexter Mendoza, MD

Module 2Lung Cancer Imaging Interventions and Advancements

  • Spectrum of Lung Ablation Indications: From Early-Stage Lung Cancer to Palliative Care—Florian J. Fintelmann, MD
  • Lung Cancer Treatment: Complications and Pitfalls—Saurabh Agarwal, MD
  • Future Advancements in Lung Cancer Care Continuum—Subba R. Digumarthy, MD
  • Past, Present, and Future of Lung Cancer Screening—Rydhwana Hossain, MD

Module 3CT Colonography Technique and Interpretation

  • Preparing Patients for CT Colonography—Abraham Dachman, MD
  • CT Colonography Radiation Dose: How Low Can You Go?—Kevin J. Chang, MD
  • CT Colonography Interpretation—Mariya Kobi, MD
  • CT Colonography Pitfalls and How to Avoid Them—Firas Ahmed, MD

Module 4CT Colonography Registry, Implementation, Rectal MRI

  • CT Colonography Registry—Courtney Coursey Moreno, MD
  • Practical Implementation of a CT Colonography Service—Cecelia Brewington, MD, FACR
  • Rectal Cancer MRI: A Practical User's Guide to Primary Staging—Zahra M. Kassam, MD
  • MRI for Evaluation of Treatment Response in Rectal Cancer—Mukesh G. Harisinghani, MD (2004 Figley Fellow)

Module 5Breast Cancer: Background History, BI-RADS, Ultrasound

  • The History of Screening Mammography—Debra S. Copit, MD
  • Digital Breast Tomosynthesis: Background, Benefits, and Future—Sarah M. Friedewald, MD
  • Imaging Interval Breast Cancers With Digital Breast Tomosynthesis: Epidemiologic, Biological, and Radiologic Considerations—Melissa A. Durand, MD, MS
  • The American College of Radiology BI-RADS Mammography Audit: Situations and Assessments—Donna M. Plecha, MD

Module 6Breast Cancer: BI-RADS, Tomosynthesis

  • Malignant Tumors of the Breast: An Introduction—Hannah Gilmore, MD
  • Abbreviated Breast MRI for Supplemental Screening: The Why and How of Clinical Implementation—Emily F. Conant, MD
  • Breast Cancer Screening with Ultrasound—Regina Hooley, MD
  • Contrast-Enhanced Mammography: Current Applications and Future Directions—Jordana Phillips, MD

Module 7Breast Cancer: MRI, AI and Pathology

  • Anxiety and Psychologic Distress with Breast Cancer Screening—Jessica W.T. Leung, MD
  • Disparities in Breast Cancer and Implications for Screening African American Women—Stephanie Patterson, MD
  • The Economics of Breast Cancer Screening—Dana H. Smetherman, MD
  • Breast Cancer Screening and Imaging Techniques: Artificial Intelligence—Michael D.C. Fishman, MD

Module 8Response Assessment: RECIST/IRECIST: Immune Therapy

  • RECIST 1.1 and RECIST Modifications—Kathleen Laura Ruchalski, MD
  • Tips and Pitfalls in RECIST 1.1—Jordan Mossler Anaokar, MD
  • A Primer: iRECIST in Immune Therapy—Iva Petkovska, MD
  • A Primer: Lymphoma Response Evaluation with PET/CT - The “Lugano” Family—Lacey J. McIntosh, DO, MPH

Module 9Response Assessment: Workflows, Models, New Horizons

  • Setting Up a Workflow for Oncology Treatment Response—Marta Braschi-Amirfarzan, MD
  • The Business of Performing Tumor Response Assessment in a Radiology Department—Michael L. Douek, MD
  • New Horizons: PET/MRI in Tumor Response—Matthias R. Benz, MD
  • New Horizons: The Use of Artificial Intelligence in Tumor Outcomes Assessment—Jonathan G. Goldin, MD, MBChB, PhD

Order Now

Or consider the stand-alone book.

ARRS is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.

The ARRS designates this enduring material for a maximum of 27.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

View the ARRS Return Policy.